

- **Full Name:** Omid Hamid, MD
 - **Current Position & Affiliation:** Chief, Translational Research & Immuno-Oncology Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars-Sinai Medical Care Foundation
Professor, Department of Medicine, Cedars Sinai Medical Center
 - **Country:** USA
-

- **Educational Background:**

Medical School University of Southern California, Keck School of Medicine
Los Angeles, CA

- **Professional Experience:**

Omid Hamid, MD is Chief, Translational Research and Immunotherapy and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute. As the Director of the Melanoma Center and Phase I Immuno-Oncology Program Dr Omid Hamid works to ensure that patients receive access to the most up-to-date therapeutics. Most recently, in his role with the Phase I Developmental Therapeutics Program, Dr Hamid has been instrumental in bringing new therapies from the investigational lab to the clinic for patient benefit. These therapies involve Immuno-Oncologic therapies such as PD-1 inhibitors (Keytruda, Nivolumab, Atezolizumab) and other checkpoint inhibitors, therapies against tumor angiogenesis, and targeted agents that block internal processes in tumor cell's function (braf,mek). Dr Hamid's research focus involves manipulation of a patient's immune system to attack cancer cells and maintain continuously elevated levels of immunity and discovery of novel therapies. His research began in melanoma and has now extended into paradigm shifting trials for all cancers.

Dr Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma Therapeutics. Through his role as the Chief of Immunotherapy and Translational Research patients at The Angeles Clinic have benefited from first in class, paradigm shifting drugs. Dr Hamid was an investigator in the initial trials with Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab and Vemurafenib, agents that led to significant survival benefits in the lives of our patients. Through his leadership the next phase of agents have become available to our patients. He has been a key investigator on combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies and continues to be at the forefront of drug development. His current work focuses on Next-Generation Checkpoint Inhibitors including anti-OX40, 41BB, GITR antibodies with a focus on bringing T-cell adoptive therapies and bispecific antibodies to our program.

- **Professional Organizations:**

- Medical Oncology Association of Southern California
- Southwest Oncology Group
- American Society of Clinical Oncology
- American Association for Cancer Research
- Society for Immunotherapy of Cancer
- Saint John's Health Center – Cancer Committee
- European Society for Medical Oncology

• Main Scientific Publications:

1- Immunotherapy for Melanoma: Ipilimumab, Nivolumab, Pembrolizumab and Vemurafenib; BRAF/MEK inhibitors: Through my role as the Chief of Immunotherapy and Translational Research, patients at The Angeles Clinic have benefited from first-in-class, paradigm-shifting drugs. I was an investigator in the initial trials with Ipilimumab, Nivolumab, Pembrolizumab and Vemurafenib, agents that led to significant survival benefit for melanoma patients.

- a) Shahabi V, Whitney G, **Hamid O**, Schmidt H, Chasalow SD, Alaparthi S, Jackson JR. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. **Cancer Immunology, Immunotherapy**: CII 2012 May; 61(5): 733-7.
- b) Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, **Hamid O**, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in metastatic or locally advanced, unresectable melanoma [LATE BREAKING abstract-proffered papers session]. In: **Proceedings of the European Cancer Congress**; 2013 Sept 27-Oct 1. Amsterdam
- c) Weber J, Thompson JA, **Hamid O**, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. **Clinical Cancer Research** 15(17):5591-8, Sept 2009.
- d) Robert C, Ribas A, Wolchok JD, Hodi FS, **Hamid O**, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Ellassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. **The Lancet Oncology**, EPUB first pii: S0140-6736(14)60958-2. Doi: 10.1016/S0140-6736(14)60958-2.

2- Role of BRAF/MEK inhibition and Immunotherapy with PD1-Antibodies: I have been an investigator and a leader for the next phase of agents with combinations of BRAF/MEK inhibitors and novel immune therapy with PD-1 antibodies.

- a) **Hamid, O.**, Chow, L.Q.M., Tavakkoli, F., Marshall, S., Gribbin, M.J., Karakunnel, J.J., Gray, J.E. Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies. [poster] In: Proceedings of the 51st ASCO Annual Meeting. 2015 May 29-June 2; Chicago, IL. **J Clin Oncol** 33, 2015 (suppl; abstr TPS3087).
- b) Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, **Hamid O**, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthi S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Ardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. **N Engl J Med**. 2012 Jun 28; 366 (26):2455-65.
- c) **Hamid O**, Robert C, Daud, A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Ellassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumei PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A, Safety and tumor responses with LAMBROLIZUMAB (Anti-PD-1) in Melanoma. **The New England Journal of Medicine** 2013 July 11; 369:134-144.
- d) Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, **Hamid O**, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. **Lancet Oncology**. 2012 May 19; 379 (9829):1893-901.